Skip to main content
Erschienen in: Journal of Neurology 1/2020

03.10.2019 | Original Communication

Risk factors for lymphopenia in patients with relapsing–remitting multiple sclerosis treated with dimethyl fumarate

verfasst von: Fabian Sierra Morales, Igor J. Koralnik, Shiva Gautam, Soleil Samaan, Jacob A. Sloane

Erschienen in: Journal of Neurology | Ausgabe 1/2020

Einloggen, um Zugang zu erhalten

Abstract

Objectives

To identify risk factors for DMF-induced lymphopenia and characterize its impact on T lymphocyte subsets in MS patients.

Methods

We performed a retrospective analysis of 194 RRMS patients treated with DMF at the Beth Israel Deaconess Medical Center (BIDMC) over a median of 17 months. We reviewed demographics, ethnic background, prior medication history, complete blood counts and T lymphocyte subsets. Possible lymphopenia risk factors examined included age, prior natalizumab exposure, vitamin D levels, and concomitant exposure to carbamazepine, opiates, tobacco, or steroids. Lymphopenia was defined as grade 1: absolute lymphocytes count (ALC) 800–999/μl; grade 2: ALC 500–799/μl; grade 3: ALC 200–499/μl; and grade 4: ALC < 200/μl.

Results

Of 194 DMF-treated patients, 73 (38%) developed lymphopenia and reached an ALC nadir after a median of 504 days (range 82–932). Risk of developing DMF-induced lymphopenia increased with BMI 25–30, older age, white ethnicity, non-smoking status, and lowest quartile baseline ALC. Prior exposure to natalizumab or concomitant steroid, opiates or carbamazepine/oxcarbamazepine use was not associated with lymphopenia. Compared to baseline levels, CD8 T cells were significantly more reduced than CD4 cells. CD8 counts were more commonly reduced with age or white ethnicity. Subjects with BMI 25–30 was associated with a higher risk of abnormal CD4 cell count reductions. In contrast, non-smokers were more likely to experience reductions in both CD4 and CD8 counts while on DMF.

Conclusions

Patients with low baseline lymphocyte counts, with intermediate BMI, with white ethnicity, with advanced age, or with no tobacco use, had a significantly higher incidence of lymphopenia on DMF. Intermediate BMI or lowest quartile baseline ALC predicted low CD4 levels, while advanced age or white ethnicity predicted low CD8 levels from DMF exposure.
Literatur
1.
Zurück zum Zitat Fox RJ, Miller DH, Phillips JT, Hutchinson M, Havrdova E, Kita M, Yang M, Raghupathi K, Novas M, Sweetser MT, Viglietta V, Dawson KT, CONFIRM Study Investigators (2012) Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med 367(12):1087–1097CrossRef Fox RJ, Miller DH, Phillips JT, Hutchinson M, Havrdova E, Kita M, Yang M, Raghupathi K, Novas M, Sweetser MT, Viglietta V, Dawson KT, CONFIRM Study Investigators (2012) Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med 367(12):1087–1097CrossRef
2.
Zurück zum Zitat Gold R, Kappos L, Arnold DL, Bar-Or A, Giovannoni G, Selmaj K, Tornatore C, Sweetser MT, Yang M, Sheikh SI, Dawson KT, DEFINE Study Investigators (2012) Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med 367(12):1098–1107CrossRef Gold R, Kappos L, Arnold DL, Bar-Or A, Giovannoni G, Selmaj K, Tornatore C, Sweetser MT, Yang M, Sheikh SI, Dawson KT, DEFINE Study Investigators (2012) Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med 367(12):1098–1107CrossRef
3.
Zurück zum Zitat Hoxtermann S, Nuchel C, Altmeyer P (1998) Fumaric acid esters suppress peripheral CD4- and CD8-positive lymphocytes in psoriasis. Dermatology 196:223–230CrossRef Hoxtermann S, Nuchel C, Altmeyer P (1998) Fumaric acid esters suppress peripheral CD4- and CD8-positive lymphocytes in psoriasis. Dermatology 196:223–230CrossRef
4.
Zurück zum Zitat Spencer C, Crabtree-Hartman EC, Lehmann-Horn K, Cree BA, Zamvil S (2015) Reduction of CD8+ T lymphocytes in multiple sclerosis patients treated with dimethyl fumarate. Neurol Neuroimmunol Neuroinflamm 2:e76CrossRef Spencer C, Crabtree-Hartman EC, Lehmann-Horn K, Cree BA, Zamvil S (2015) Reduction of CD8+ T lymphocytes in multiple sclerosis patients treated with dimethyl fumarate. Neurol Neuroimmunol Neuroinflamm 2:e76CrossRef
5.
Zurück zum Zitat Du Pasquier RA, Kuroda MJ, Zheng Y, Jean-Jacques J, Letvin NL, Koralnik IJ (2004) A prospective study demonstrates an association between JC virus-specific cytotoxic T lymphocytes and the early control of progressive multifocal leukoencephalopathy. Brain 127(Pt 9):1970–1978CrossRef Du Pasquier RA, Kuroda MJ, Zheng Y, Jean-Jacques J, Letvin NL, Koralnik IJ (2004) A prospective study demonstrates an association between JC virus-specific cytotoxic T lymphocytes and the early control of progressive multifocal leukoencephalopathy. Brain 127(Pt 9):1970–1978CrossRef
6.
Zurück zum Zitat Rosenkranz T, Novas M, Terborg C (2015) PML in a patient with lymphocytopenia treated with dimethyl fumarate. N Engl J Med 372(15):1476–1478CrossRef Rosenkranz T, Novas M, Terborg C (2015) PML in a patient with lymphocytopenia treated with dimethyl fumarate. N Engl J Med 372(15):1476–1478CrossRef
7.
Zurück zum Zitat Bartsch T, Rempe T, Wrede A, Leypoldt F, Brück W, Adams O, Rohr A, Jansen O, Wüthrich C, Deuschl G, Koralnik IJ (2015) Progressive neurologic dysfunction in a psoriasis patient treated with dimethyl fumarate. Ann Neurol 78(4):501–514CrossRef Bartsch T, Rempe T, Wrede A, Leypoldt F, Brück W, Adams O, Rohr A, Jansen O, Wüthrich C, Deuschl G, Koralnik IJ (2015) Progressive neurologic dysfunction in a psoriasis patient treated with dimethyl fumarate. Ann Neurol 78(4):501–514CrossRef
8.
Zurück zum Zitat Lehmann-Horn K, Penkert H, Grein P, Leppmeier U, Teuber-Hanselmann S, Hemmer B, Berthele A (2016) PML during dimethyl fumarate treatment of multiple sclerosis: how does lymphopenia matter? Neurology 87(4):440–441CrossRef Lehmann-Horn K, Penkert H, Grein P, Leppmeier U, Teuber-Hanselmann S, Hemmer B, Berthele A (2016) PML during dimethyl fumarate treatment of multiple sclerosis: how does lymphopenia matter? Neurology 87(4):440–441CrossRef
9.
Zurück zum Zitat Baharnoori M, Lyons J, Dastagir A, Koralnik I, Stankiewicz JM (2016) Nonfatal PML in a patient with multiple sclerosis treated with dimethyl fumarate. Neurol Neuroimmunol Neuroinflamm 3(5):e274CrossRef Baharnoori M, Lyons J, Dastagir A, Koralnik I, Stankiewicz JM (2016) Nonfatal PML in a patient with multiple sclerosis treated with dimethyl fumarate. Neurol Neuroimmunol Neuroinflamm 3(5):e274CrossRef
10.
Zurück zum Zitat Longbrake E, Naismith RT, Parks BJ, Wu GF, Cross AH (2015) Dimethyl fumarate-associated lymphopenia: risk factors and clinical significance. Mult Scler J Exp Transl Clin. 1:1–8 Longbrake E, Naismith RT, Parks BJ, Wu GF, Cross AH (2015) Dimethyl fumarate-associated lymphopenia: risk factors and clinical significance. Mult Scler J Exp Transl Clin. 1:1–8
11.
Zurück zum Zitat Silverman DA, Chapron DJ (1995) Lymphopenic effect of carbamazepine in a patient with chronic lymphocytic leukemia. Ann Pharmacother 29(9):865–867CrossRef Silverman DA, Chapron DJ (1995) Lymphopenic effect of carbamazepine in a patient with chronic lymphocytic leukemia. Ann Pharmacother 29(9):865–867CrossRef
12.
13.
Zurück zum Zitat Pintado CO, Carracedo J, Rodríguez M, Pérez-Calderón R, Ramírez R (1996) 1 alpha, 25-dihydroxyvitamin D3 (calcitriol) induces apoptosis in stimulated T cells through an IL-2 dependent mechanism. Cytokine 8(5):342–345CrossRef Pintado CO, Carracedo J, Rodríguez M, Pérez-Calderón R, Ramírez R (1996) 1 alpha, 25-dihydroxyvitamin D3 (calcitriol) induces apoptosis in stimulated T cells through an IL-2 dependent mechanism. Cytokine 8(5):342–345CrossRef
14.
Zurück zum Zitat Martinesi M, Treves C, d’Albasio G, Bagnoli S, Bonanomi AG, Stio M (2008) Vitamin D derivatives induce apoptosis and downregulate ICAM-1 levels in peripheral blood mononuclear cells of inflammatory bowel disease patients. Inflamm Bowel Dis 14(5):597–604CrossRef Martinesi M, Treves C, d’Albasio G, Bagnoli S, Bonanomi AG, Stio M (2008) Vitamin D derivatives induce apoptosis and downregulate ICAM-1 levels in peripheral blood mononuclear cells of inflammatory bowel disease patients. Inflamm Bowel Dis 14(5):597–604CrossRef
15.
Zurück zum Zitat Arunabh S, Pollack S, Yeh J, Aloia JF (2003) Body fat content and 25-hydroxyvitamin D levels in healthy women. J Clin Endocrinol Metab 88(1):157–161CrossRef Arunabh S, Pollack S, Yeh J, Aloia JF (2003) Body fat content and 25-hydroxyvitamin D levels in healthy women. J Clin Endocrinol Metab 88(1):157–161CrossRef
16.
Zurück zum Zitat Winters SJ, Chennubhatla R, Wang C, Miller JJ (2009) Influence of obesity on vitamin D-binding protein and 25-hydroxy vitamin D levels in African American and white women. Metabolism 58(4):438–442CrossRef Winters SJ, Chennubhatla R, Wang C, Miller JJ (2009) Influence of obesity on vitamin D-binding protein and 25-hydroxy vitamin D levels in African American and white women. Metabolism 58(4):438–442CrossRef
17.
Zurück zum Zitat Šilhavý J, Zídek V, Mlejnek P, Landa V, Šimáková M, Strnad H, Oliyarnyk O, Škop V, Kazdová L, Kurtz T, Pravenec M (2014) Fumaric acid esters can block pro-inflammatory actions of human CRP and ameliorate metabolic disturbances in transgenic spontaneously hypertensive rats. PLoS One 9(7):e101906CrossRef Šilhavý J, Zídek V, Mlejnek P, Landa V, Šimáková M, Strnad H, Oliyarnyk O, Škop V, Kazdová L, Kurtz T, Pravenec M (2014) Fumaric acid esters can block pro-inflammatory actions of human CRP and ameliorate metabolic disturbances in transgenic spontaneously hypertensive rats. PLoS One 9(7):e101906CrossRef
18.
Zurück zum Zitat Higuchi T, Omata F, Tsuchihashi K, Higashioka K, Koyamada R, Okada S (2016) Current cigarette smoking is a reversible cause of elevated white blood cell count: cross-sectional and longitudinal studies. Prev Med Rep 4:417–422CrossRef Higuchi T, Omata F, Tsuchihashi K, Higashioka K, Koyamada R, Okada S (2016) Current cigarette smoking is a reversible cause of elevated white blood cell count: cross-sectional and longitudinal studies. Prev Med Rep 4:417–422CrossRef
19.
Zurück zum Zitat Munger KL, Levin LI, Hollis BW, Howard NS, Ascherio A (2006) Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. JAMA 296(23):2832–2838CrossRef Munger KL, Levin LI, Hollis BW, Howard NS, Ascherio A (2006) Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. JAMA 296(23):2832–2838CrossRef
20.
Zurück zum Zitat Bargman JM, Silverman ED, Klein MH (1989) Effect of 1,25-dihydroxyvitamin D3 in vivo on circulating T lymphocytes. Miner Electrolyte Metab 15(6):359–364PubMed Bargman JM, Silverman ED, Klein MH (1989) Effect of 1,25-dihydroxyvitamin D3 in vivo on circulating T lymphocytes. Miner Electrolyte Metab 15(6):359–364PubMed
21.
Zurück zum Zitat Ritterhouse LL, Lu R, Shah HB, Robertson JM, Fife DA, Maecker HT, Du H, Fathman CG, Chakravarty EF, Scofield RH, Kamen DL, Guthridge JM, James JA (2014) Vitamin d deficiency in a multiethnic healthy control cohort and altered immune response in vitamin D deficient European–American healthy controls. PLoS One 9(4):e94500CrossRef Ritterhouse LL, Lu R, Shah HB, Robertson JM, Fife DA, Maecker HT, Du H, Fathman CG, Chakravarty EF, Scofield RH, Kamen DL, Guthridge JM, James JA (2014) Vitamin d deficiency in a multiethnic healthy control cohort and altered immune response in vitamin D deficient European–American healthy controls. PLoS One 9(4):e94500CrossRef
22.
Zurück zum Zitat Smolders J, Damoiseaux J, Menheere P, Hupperts R (2008) Vitamin D as an immune modulator in multiple sclerosis. J Neuroimmunol 194(1–2):7–17CrossRef Smolders J, Damoiseaux J, Menheere P, Hupperts R (2008) Vitamin D as an immune modulator in multiple sclerosis. J Neuroimmunol 194(1–2):7–17CrossRef
23.
Zurück zum Zitat Mili F, Flanders WD, Boring JR, Annest JL, Destefano F (1991) The associations of race, cigarette smoking, and smoking cessation to measures of the immune system in middle-aged men. Clin Immunol Immunopathol 59(2):187–200CrossRef Mili F, Flanders WD, Boring JR, Annest JL, Destefano F (1991) The associations of race, cigarette smoking, and smoking cessation to measures of the immune system in middle-aged men. Clin Immunol Immunopathol 59(2):187–200CrossRef
24.
Zurück zum Zitat Nowicki MJ, Karim R, Mack WJ, Minkoff H, Anastos K, Cohen M, Greenblatt RM, Young MA, Gange SJ, Levine AM (2007) Correlates of CD4+ and CD8+ lymphocyte counts in high-risk immunodeficiency virus (HIV)-seronegative women enrolled in the women’s interagency HIV study (WIHS). Hum Immunol 68(5):342–349CrossRef Nowicki MJ, Karim R, Mack WJ, Minkoff H, Anastos K, Cohen M, Greenblatt RM, Young MA, Gange SJ, Levine AM (2007) Correlates of CD4+ and CD8+ lymphocyte counts in high-risk immunodeficiency virus (HIV)-seronegative women enrolled in the women’s interagency HIV study (WIHS). Hum Immunol 68(5):342–349CrossRef
25.
Zurück zum Zitat Mehta D, Miller C, Arnold D, Bame E, Bar-Or A, Gold R, Hanna J, Kappos L (2019) Effect of dimethyl fumarate on lymphocytes in RRMS Implications for clinical practice. Neurology 92:e1–e15CrossRef Mehta D, Miller C, Arnold D, Bame E, Bar-Or A, Gold R, Hanna J, Kappos L (2019) Effect of dimethyl fumarate on lymphocytes in RRMS Implications for clinical practice. Neurology 92:e1–e15CrossRef
Metadaten
Titel
Risk factors for lymphopenia in patients with relapsing–remitting multiple sclerosis treated with dimethyl fumarate
verfasst von
Fabian Sierra Morales
Igor J. Koralnik
Shiva Gautam
Soleil Samaan
Jacob A. Sloane
Publikationsdatum
03.10.2019
Verlag
Springer Berlin Heidelberg
Erschienen in
Journal of Neurology / Ausgabe 1/2020
Print ISSN: 0340-5354
Elektronische ISSN: 1432-1459
DOI
https://doi.org/10.1007/s00415-019-09557-w

Weitere Artikel der Ausgabe 1/2020

Journal of Neurology 1/2020 Zur Ausgabe

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.